Category Archives: General Venture Capital

Today we announced the closing of Atlas Venture Fund XIV, a $450M investment vehicle focused exclusively on early stage biotech investing. With the closing of Fund XIV, we’re privileged to be able to continue backing innovative new biotech companies for

At the end of every year, we host both our Atlas Venture Annual Meeting for our fund investors (Limited Partners) and our Atlas Retreat for senior industry executives.  As a kickoff for these two meetings, we typically open with a

2018 was a gangbuster year for VC-funding into startups, reaching levels not seen since the height of the dot-com and genomics era. According to recent data from the NVCA/Pitchbook, VC across all sectors topped $130B invested across nearly 9000 deals

As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the

President Trump’s tenure as the 45th POTUS has begun with even more fireworks than most pundits predicted – protests, marches, bans, and lots of other drama. The coastal Twitter/Facebook bubbles are exploding with anger and rage, while the Trump populists

Venture capital has been on a good run over the past few years across a range of sectors; even with recent slowdown relative to 2014-2015, venture-backed investments remain above historic averages.  In fact, the first three quarters of 2016 alone

Biotech has been one of the hottest sectors in the venture capital asset class over the past few years. Strong IPO and M&A markets have put wind in the sails of the space since 2012, and robust investment activity has

Venture capital in biotech has had a great run over the past few years: funding going to private biotech companies is at historic highs, new venture funds are getting raised, and exits have been happening via robust IPO and M&A

Biotech has been on a tear over the past few years supported by a combination of scientific advances, great IPO and M&A exit environments, and robust capital markets for fundraising. Watching the public indices gives a good indicator of broader

Venture-backed biotechs continue their blistering pace of funding. According to the latest MoneyTree Report from PricewaterhouseCoopers (PwC) and the National Venture Capital Association (NVCA), with data from Thomson Reuters, over $2.1B was invested in biotech companies in 2Q 2015, bringing the year

Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well. Last week the quarterly Thomson Reuters data on venture capital funding came out via

Biotech is definitely red-hot, and has been for the past eight quarters. Immuno-oncology, cancer metabolism, gene therapy, orphan diseases, NASH, autoimmune – there’s a broad range of disease settings that are capturing the excitement and imagination of investors today. With some

As with everything in life, it’s always about the people.  Bet the jockey, not the horse.  Great entrepreneurs and C-level executives are very hard to come by in R&D-intensive biotech companies, and its probably one of the biggest bottlenecks in

The ever-shrinking number of biotech venture capital firms was a common refrain during the 2008-2012 period; it’s true that a large number of firms went under, closed their doors for new investments, or moved into zombie status.  I wrote on

The world is awash in cool new tech startups and poised for “A Cambrian Moment”, according to a recent special report from the Economist. For those that haven’t read it, it’s a very interesting set of articles about the trends

Return distributions in venture capital across different sectors have been a frequent source of commentary, and new data from Correlation Ventures provides further substrate for that theme. I’ve highlighted data from Correlation Ventures (CV) in the past, looking at top

Tis the season for reflecting and predicting, so I figured I’d follow the custom and share some of my thoughts about the state of biotech in 2013 and the year to come. Reflections on 2013. The Biotech IPO Returns.  This

The broad underperformance of the venture capital asset class during the past decade is widely discussed; there’s a frequently-cited assertion that U.S. venture returns trailed the overall public equity stock market in the 2000s. Few if any published analyses have

Last month legendary investor Vinod Khosla commented that 95% of VCs add “zero value” and 80% probably “add negative value” in how they advise startup companies in their portfolio.  This is a stunning indictment of the VCs that Khosla has

Successful deals in venture capital take on a life of their own, especially the rare massive outlier return.  Unfortunately for venture capitalists, Facebooks and Twitters are very rare. Understanding the nature of “winners” requires a good grounding in what a

There are lots of myths about venture capital and biotech in particular, as noted previously on this blog.  Many of these myths are deeply held beliefs about returns, what works and what doesn’t, and the state of the industry.  Told

Biotech just takes too long, especially when compared to the overnight success of technology ventures, or so the oft-cited criticism of venture-backed biotech’s perceived longer holding period goes. Despite being a well-accepted belief  held by most venture professionals, LP’s, and

Last week, Atlas Venture closed Fund IX at $265M, as reported this morning by Dan Primack.  We set out to raise $250M, and closed above-target with great support from our existing LP’s and some great new ones.  With this closing,

Euphoria in the markets seems like a common theme these days.  In fact, this week the NASDAQ Biotech Index (NBI) hit its all time high, even higher than in the 2000 genomics bubble.  It’s up 49% since Jan 2012.  Add

Venture capital is often called an apprenticeship business in large part because experience matters and takes time to accumulate.  But successful firms are able to translate and transfer experiential wisdom through institutional memory, which involves codifying what works and what

As 2013 begins, and the JPM conference is behind us, it’s a great time to reflect on the state of the biotech industry and the sentiments around early stage investing in particular.  While pessimism abounds in many corners about the

Most of the news flow around the JPM Healthcare conferences centers around the main event: public companies presenting their earnings forecasts, R&D updates, new partnering deals, and the like.  There’s also a small private company track at JPM, and there are

The recycling of equity capital through realized returns is a critically important element of biotech investing.  When public biotech companies get bought, like Genentech by Roche, or smaller deals like Cougar by J&J, a large number of biotech-focused equity funds

The translation of cutting-edge science into new clinically-relevant therapeutics is the ultimate goal of many academic investigators, industry researchers, and investors.  This stage of R&D is the most challenging, and typically frought with scientific and technical risks: taking a new

Much of the public dialogue about venture capital returns is based more on myth than fact, which reinforces inappropriately limited views of relative sector attractiveness, underlying risk profiles, and the “business models” that work in venture.  A big part of

Like many things driven by human nature, venture-backed biotech boardrooms often swing between the emotions of fear and greed.  Fear of losing your shirt, or the greed of demanding more of the story than is warranted.  It’s the age-old imbalance

Correlation Ventures, a new analytics-driven venture firm, just came out with some interesting data on US venture capital returns over the past decade. Instead of taking a “birth” vintage approach to returns, which is the way venture fund vintages and

Biotech IPOs have long been viewed with skeptism, especially over the past few years in comparison to the high-flying media darlings in the Tech space.  But recently a number of the social media phenoms have fallen from grace: Groupon is

Pharma have been retooling their therapeutic strategies and R&D priorities considerably over the past decade, shifting in and out of various disease areas.  As they are the eventual home for many of the biotech programs we and other early stage

“We Have Met the Enemy… And He is Us” is the very fitting title of a recent report on the state of the VC market with a focus on the GP-LP relationship.  This thoughtful and thankfully analytical report highlights a

Twenty years ago the biotech world was in the midst of one of the best IPO windows in its history.  Nearly a hundred biotech companies went public from 1991-1994, including a number of the great companies that have become household

Over the past decade biotech investments made by diversified venture capital firms have outperformed those by healthcare-focused firms.  Its unclear why the difference exists, but the historical data suggest it’s a striking differential. Examining the NVCA Benchmarking Database powered by

Everyone has heard of the monster returns to some venture funds from high-flyng social media and technology companies: Facebook’s potential 800x for Accel, Google’s 350x for KPCB and Sequoia, Zynga’s 100x+ for Union Square, Foundry, and Avalon.  These single big

Having a highly functional and productive Board of Directors is a key ingredient for success for most companies, but its of particular importance for early stage startups. The web is full of advice around what are the “best practices” for venture-backed

Biotech pundits often talk about the challenge of raising an initial round of capital for drug discovery startups, highlighting the perceived “gap” in early stage funding.   And it certainly isn’t easy raising that first significant round of institutional capital.  But